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Background and aims: Inhalation of hypertonic saline (HTS) has short term positive effects on
airways clearance in non-cystic fibrosis (CF) bronchiectasis, however its long term effects are
unknown. The aim of this study was to determine the effect of HTS 6% on exacerbations,
quality of life (QOL) and respiratory function over 12 months in non-CF bronchiectasis.
Methods: Forty patients were randomised to inhale isotonic saline (IS) 0.9% or HTS 6% daily for
12 months. Participants recorded their symptoms in a daily diary. Quality of life and respiratory
function were measured after three, six and 12 months. Number of exacerbations and changes
in sputum colonisation were recorded at 12 months. Participants, assessors and clinicians were
blinded to group allocation.
Results: The exacerbation rate at 12 months was similar in the two groups and similar clinically
significant improvements in QOL were seen in both groups. The FEV1 increased in both groups
after six months (mean 90 ml, 95% confidence interval 11e169 ml) with no difference between
groups (p Z 0.394). The FEF25e75% significantly improved at all time points (mean increase at
12 months 187 ml, 69e304 ml) with no difference between groups (p Z 0.705). There was
a reduction in sputum colonisation in both groups (p Z 0.046).
Conclusions: Inhalation of HTS or IS has similar effects on exacerbations, QOL, sputum coloni-
sation and respiratory function over 12 months in non-CF bronchiectasis. The trial was regis-
tered with both Clinical Trials.gov e NCT00484263 and Australian New Zealand Clinical Trials
Registry e ACTRN12607000367448.
ª 2012 Elsevier Ltd. All rights reserved.9076 3450; fax: þ61 3 9076 2702.
d.org.au, sckn@bigpond.net.au (C.H.H. Nicolson).
2 Elsevier Ltd. All rights reserved.
662 C.H.H. Nicolson et al.Introduction events. The study was registered with both the ClinicalNon-cystic fibrosis (CF) bronchiectasis is a chronic lung
disease characterised by permanent dilatation of the
bronchi. Predominant features include chronic cough and
abnormal sputum production, leading to mucus accumula-
tion, recurrent infections and decreased lung function,1e3
which result in a significant reduction in quality of life
(QOL).4e6 Airway hygiene is usually maintained by the
mucociliary escalator which is influenced by both physio-
logical factors and disease.7,8 Patients with non-CF bron-
chiectasis are not able to rely on this mechanism to clear
their secretions and often need daily physiotherapy9e11
which has traditionally included the active cycle of
breathing technique, postural drainage and positive expi-
ratory pressure therapy.
Hypertonic saline (HTS) 4%e7% is reported to improve
hydration of the airway surface and the rheology and
transportability of sputum.12e14 It may also have anti-
inflammatory effects.15 A long term randomised
controlled trial demonstrated improvements in lung func-
tion and reductions in the frequency of exacerbations and
antibiotic use in individuals with CF when compared to
isotonic saline (IS).16 Whether or not the same benefits can
be achieved in non-CF bronchiectasis is still to be deter-
mined. A short term crossover study17 showed that HTS 7%
was more effective than IS in assisting with expectoration
of sputum and can safely be used in non-CF bronchiectasis,
however no long term studies have been conducted.
The aim of this study was to establish whether the long
term inhalation of HTS 6% decreased pulmonary exacerba-
tions and the incidence of sputum colonisation and
improved QOL and lung function.Methods
Participants
Adults with bronchiectasis, confirmed by high resolution
computed tomography, were recruited from the respiratory
medicine department of a tertiary hospital in Melbourne,
Australia.
Participants were eligible to be included if they were
over 18 years old, were clinically stable, produced sputum
daily and reported at least two exacerbations requiring
antibiotics per year for the previous two years. They were
excluded if they had CF, their FEV1 decreased by more than
15% after the HTS challenge or their FEV1 was less than 1 L
at baseline. Ethical approval was granted by the Alfred
Hospital Ethics Committee and written informed consent
was obtained from all participants.
Study design
A prospective 12 month randomised controlled trial
comparing IS with HTS 6% was conducted from January 2008
to October 2009. Assessors, therapists, participants and
their physicians were blinded to treatment allocation. A co-
investigator, who had no role in treatment allocation or
outcome assessment, was un-blinded to manage adverseTrials Protocol Registration system (NCT00484263) and the
Australian New Zealand Clinical Trials Registry
(ACTRN12607000367448).Measurement
At the screening visit spirometry was measured using
standard protocols.18 Salbutamol (200 mg) was then
administered via a metered dose inhaler and spacer and
spirometry was repeated at least five minutes later.
Hypertonic saline 6% (5 ml) was then inhaled via an Aero-
nebGo mouthpiece micropump nebuliser (Niche Medical,
Perth, Australia). Spirometry was repeated 20 minutes
later. If the FEV1 did not fall by 15%, participants were
deemed safe to proceed with the trial.
Provided there were no signs or symptoms of a pulmo-
nary exacerbation, participants returned two weeks later
for their baseline visit. Spirometry was repeated and
a sputum sample obtained for microbiology and culture.
Exacerbations requiring antibiotics over the previous two
years were recorded.
Two questionnaires, validated for non-CF bronchiec-
tasis, were used to measure QOL: the St George’s Respira-
tory Questionnaire (SGRQ)19 and the Leicester Cough
Questionnaire (LCQ).20 The minimal important difference
(MID) for the SGRQ is four points for each domain and for
the total score, with lower scores indicating better health-
related QOL.21 The MID for the LCQ is 0.2 (physical), 0.2
(social), 0.8 (psychological) and 1.3 for the total score, with
higher scores indicating better QOL.22 The number of
people who achieved the MID for both QOL measures was
calculated for each group.
Participants were then randomised (using a computer
generated randomisation sequence concealed using sealed
opaque envelopes) to receive either IS or HTS for the
duration of the trial. The sachets of saline, distributed by
the clinical trials pharmacy, were of the same size and
appearance. Prior to commencing the inhalation of saline,
participants were instructed to inhale two 100 mg puffs of
salbutamol (Ventolin) via a Volumatic spacer (Allen &
Hanburys). Whilst inhaling 5 ml of the saline solution via the
nebuliser they were instructed to vary their inspiratory
volume in cycles of larger and smaller breaths to optimise
the deposition of the saline. This routine was repeated
twice a day for 12 months and was documented in a home
diary.
Participants were instructed to use only the nebulised
saline for airways clearance. There were no restrictions on
prescribed medications. The daily home diary recorded
adherence, changes in medications and symptoms (a
change in sputum volume or colour, new or increased
haemoptysis, increased cough, dyspnoea, lethargy, a fever
or increased sinus discharge). An exacerbation was defined
as recording at least three symptoms in one day for two or
more consecutive days.16 Exacerbations requiring
commencement of antibiotics and exacerbations based on
symptoms only, were calculated. At the end of each month,
cough frequency was recorded using a visual analogue scale
(VAS) with anchors of “never” and “continuously
throughout the treatment”. Home diaries were returned at
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external assessor.
The co-ordinator contacted the participants by tele-
phone each week for the first month and then monthly for
the remainder of the trial to reinforce the procedure and
the completion of the home diary. Concerns regarding their
treatment or their general health were directed to the un-
blinded co-investigator.
Spirometry and QOL were repeated at three, six and 12
months when participants returned for review. Self re-
ported hospital visits were recorded. At the 12 month visit,
a sputum sample was obtained and participants and the
treating physiotherapist were asked to nominate if they had
been inhaling the “strong” or the “weak” salt solution, to
assess the efficacy of blinding.Figure 1 Study flow chart.
Table 1 Baseline characteristics of the 40 participants.
IS (0.9%) HTS (6%)
Age (years) 56 (15) 58 (15)
Gender (M/F) 8/12 7/13
BMI (kg/m2) 28.2 (5.0) 27.9 (5.4)Statistical analysis
Data were expressed as mean (SD) for normally distributed
data or median and interquartile ranges (IQR) for data that
were not normally distributed. Statistical analysis was
performed for parametric data using a two way analysis of
variance to account for group and time interaction (SPSS
V.17.0; SPSS Inc). Post-hoc testing was conducted where
a significant main effect was evident. Non-parametric data
were compared between groups using the Mann Whitney U
test. The significance level was set at p < 0.05.
For a 90% probability of detecting a difference in the
number of exacerbations 30 subjects were required. This is
based on the assumption that the true difference between
groups is 0.5 exacerbations with a standard deviation of 0.4
exacerbations.16 For a 90% probability of detecting
a difference between groups in FEV1, 32 subjects were
required. This is based on the assumption that the true
difference between groups was 120 ml with a standard
deviation of 100 ml.16 To account for an anticipated loss to
follow-up of 25%, a total of 40 subjects were recruited.FEV1 (% pred) 80.4 (21.1) 84.8 (20.5)
FVC (% pred) 97.1 (18.0) 98.5 (17.8)
FEF25e75% (% pred) 49.0 (24.8) 57.7 (25.4)
FEV1/FVC (% pred) 0.67 (0.11) 0.69 (0.11)
Self reported exacerbations
Median (IQR) 5.5 (3.1) 5.0 (3.9)
Range 10.0 13.0
Previous physiotherapy (%)
Nil 7.5 7.5
ACBT 32.5 42.5
PEP therapy 22.5 32.5
Postural drainage 25.0 17.5
Results presented as mean (SD) unless otherwise stated. %
predicted spirometry values calculated using the equations of
Knudson,23 BMI: body mass index, FEV1: forced expiratory
volume in 1 s, FVC: forced vital capacity, FEF25e75%: forced
expiratory flow at 25e75% of the forced vital capacity, Self
reported exacerbations: number of exacerbations self reported
over the previous 12 months prior to trial, IQR: Interquartile
range, Previous physiotherapy %: percentage of total partici-
pants who were adhering to physiotherapy airways clearance
techniques in the 12 months prior to commencement of the
trial, ACBT: the active cycle of breathing technique, PEP:
positive expiratory pressure therapy.Results
Forty eight patients were screened (Fig. 1) with eight
excluded prior to randomisation. Four declined inclusion
and four did not meet the inclusion criteria: one due to
a fall in FEV1 following the HTS challenge and three due to
screening FEV1 values less than 1 L. Two participants from
the HTS group withdrew at the three month assessment
visit. One suffered from depression and was unable to
adhere to the daily routine and the other declined further
treatment. Both participants returned for all scheduled
visits for measurement of outcomes and were included in
the intention to treat analysis.
The baseline characteristics of the 40 randomised
participants are shown in Table 1.
There was no significant difference between the two
groups for any of the demographic variables at baseline or
in the number of self reported exacerbations in the 12
months preceding the trial (p Z 0.86). As expected, there
was a 3:2 ratio of women to men in both groups and all of
the participants had mild to moderate lung disease based
on spirometry. There was only one protocol deviation
Table 2 Number of exacerbations over 12 months.
IS (0.9%) HTS (6%) p value
Exacerbations 1.0 (0e4) 3.0 (0e6) 0.24
Exacerbations
requiring antibiotics
0.5 (0e3) 1.0 (0e2.5) 0.99
Exacerbation days 2.0 (0e26) 12.0 (1e26) 0.57
Exacerbation days
requiring antibiotics
1.0 (0e19.5) 2.0 (0e7) 0.77
Data are median (IQR). IS: isotonic saline, HTS: hypertonic
saline. p value for comparison of isotonic saline and hypertonic
saline over 12 months.
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lator from salbutamol to terbutaline.
There was no significant difference between groups for
the number of exacerbations over the 12 months of the trial
(Table 2). Nor was there a significant difference between
groups for hospital admissions (p Z 0.34) or hospital days
(pZ 0.36). Four participants had hospital admissions, three
in the IS group for three, five and 61 days respectively and
one in the HTS group for 68 days.
Quality of life significantly improved in both groups in all
domains of both the SGRQ and the LCQ after three, six and
12 months (Tables 3 & 4). There were trends for more rapid
improvement in the symptom and activity domains of the
SGRQ in the HTS group over the first three months however
no difference between groups was evident at 12 months for
either the LCQ or the SGRQ (Figs. 2 & 3).
At baseline 60% of the participants in the IS group and
55% in the HTS group had a positive sputum culture for
Pseudomonas, Haemophilus, Aspergillus, Staphylococcus
aureus or Streptococcus with no significant difference in
isolates between groups. At the completion of the trial
there was a significant decrease in both groups with only
15% in each group having a positive sputum culture
(pZ 0.046). There were no significant differences between
groups in cough frequency reported by VAS at three
(p Z 0.39), six (p Z 0.17) or 12 months (p Z 0.60).
There was no statistically or clinically significant
difference in lung function between treatment groups at
any time point (Table 5) however, significant improvements
in FEV1 and FEF25e75% with respect to time were evident.Table 3 Impact on QOL e St George’s Respiratory Questionnair
Baseline 3 m
Symptom
IS 64.1 (16.1) 57.0 (17.5)b
HTS 64.3 (14.2) 48.5 (21.0)b
Activity
IS 39.4 (22.2) 35.4 (22.4)b
HTS 50.1 (24.4) 39.8 (28.5)b
Impact
IS 33.5 (17) 27.2 (17.9)b
HTS 35.6 (16.9) 26.8 (19.6)b
Data are mean (standard deviation). IS: isotonic saline, HTS: hyperto
a p value for group  time interaction.
b p < 0.05 compared to baseline.Compared to baseline, FEV1 increased in both groups after
six months (mean 90 ml; 11 to 169; pZ 0.04), but this was
not sustained at 12 months and there was no difference
between groups (mean difference 0.06; 95% confidence
interval 0.08 to 0.20; pZ 0.39). FEF25e75% increased at all
time points (mean 187 ml; 69 to 304; p Z 0.001) in both
groups with no difference between groups (0.04; 0.19 to
0.28; p Z 0.71). There was no significant interaction
between group allocation and time for FVC (p Z 0.67) but
there was a trend towards a reduction in FVC in both groups
at 12 months with no difference between groups (0.09;
0.07 to 0.25; p Z 0.26).
There were three adverse events in the HTS group. One
participant reported chest tightness during inhalation
which resolved with treatment of an underlying acute
exacerbation. Another reported an episode of hypertension
which resolved without further intervention. This was
judged by the patient’s physician to be unrelated to the
intervention. Both participants continued in the trial
without incident for the remainder of the 12 months. The
third participant experienced an episode of rapid atrial
fibrillation requiring attendance at the emergency depart-
ment and subsequently elected to cease the saline inhala-
tion prior to the three month assessment. There were no
adverse events in the IS group.
Self reported adherence to therapy over 12 months was
not significantly different between groups (p Z 0.86). The
median number of inhalations missed over 12 months was
103 (IQR 25-226) in the IS group and 56 (IQR 22-311) in the
HTS group. There was a significant decrease in adherence
to therapy across all participants after six months (median
28 missed inhalations in the first six months versus 47
missed inhalations in the second six months p  0.001).
Fifty percent of participants correctly identified the
treatment they had been receiving and the treating phys-
iotherapist identified the correct therapy in 58% of the
participants at the final visit. On completion of the trial 73%
of participants chose to continue nebulised saline (IS,
n Z 6, HTS, n Z 23).Discussion
This randomised controlled trial is the first long term study
examining the effect of inhaled HTS 6% in non-CFe.
6 m 12 m p valuea
0.18
51.2 (19.8)b 50.7 (22.7)b
57.6 (20.0)b 52.3 (22.9)b
0.18
31.0 (21.3)b 34.7 (25.1)b
33.6 (25.2)b 37.4 (25.9)b
0.60
22.8 (15.2)b 23.3 (19.1)b
22.0 (13.5)b 27.7 (19.3)b
nic saline, m: months.
Table 4 Impact on QOL e Leicester Cough Questionnaire.
Baseline 3 m 6 m 12 m p valuea
Physical 0.21
IS 4.2 (1.7) 4.9 (1.0)b 5.1 (1.4)b 5.3 (1.3)b
HTS 4.4 (1.0) 5.3 (1.0)b 5.0 (1.1)b 5.1 (1.1)b
Psychological 0.06
IS 3.9 (1.5) 5.0 (1.4) 5.4 (1.4)b 5.5 (1.6)b
HTS 4.7 (1.3) 5.9 (1.1)b 5.3 (1.0)b 5.7 (1.0)b
Social 0.17
IS 4.4 (1.4) 5.2 (1.3)b 5.6 (1.3)b 5.7 (1.4)b
HTS 4.6 (1.2) 5.7 (1.4)b 5.5 (1.0)b 5.6 (1.0)b
Data are mean (standard deviation). IS: isotonic saline, HTS: hypertonic saline, m: months.
a p value for group  time interaction.
b p < 0.05 compared to baseline.
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ated and resulted in similar clinically important benefits
with significant improvements seen in QOL, lung function,
and sputum colonisation in both groups when inhaling
either IS or HTS. There was no difference between groups in
exacerbation rates.
This study did not identify any clinically important
superiority of inhaled HTS over IS in non-CF bronchiectasis.
This is perhaps contrary to a previous finding where HTS was
found to be more effective than IS in decreasing sputum
viscosity and increasing sputum yield during four single
treatments in patients with non-CF bronchiectasis who
produced less than 10 mg of sputum each day.17 The
differences in results may be explained by the extended
length of our treatment or the different outcomes
measured in the two trials. Hypertonic saline 7% inhalation
has also been found to be superior to IS in patients with CF,
with significant improvements in QOL and lung function16,24
and a significant decrease in exacerbations.16 Our finding of
no difference between groups may be due to the smaller
sample size or to the electrolyte content and rheology of CF
sputum which differ from that of non-CF sputum.25 This
confirms previous observations that treatments beneficialFigure 2 SGRQ Totals. No significant difference between
groups at any time point.for CF26,27 may not have the same effects in non-CF
bronchiectasis.
It is possible that HTS may have anti-inflammatory as
well as rheological effects on airway mucous in CF bron-
chiectasis by clearance of 1L-8 and protease activity such
as neutrophil elastase.15 Further studies are required to
ascertain if sub-groups of disease severity and aetiology are
more likely to respond to varied or higher sodium chloride
concentrations. It is interesting to note that nearly three
quarters of the participants chose to continue nebulised
saline suggesting that overall acceptance and perception of
benefits was high.
Clinically relevant benefits were evident in both
treatment groups over 12 months. The presence of
organisms such as Pseudomonas aeruginosa, Haemophilus
influenzae and Staphylococcus aureus are associated with
reduced QOL.2,4,28 The significant decrease in the pres-
ence of these organisms following the use of IS or HTS may
be attributable to the improved hydration of the airway,
resulting in enhanced airways clearance. It is important to
note that prior to commencement on the trial 85% of the
participants were regularly using airways clearance
techniques.Figure 3 LCQ Totals. No significant difference between
groups at any time point.
Table 5 Lung function.
Baseline 3 months 6 months 12 months p value
FEV1 0.70
IS 2.16 (0.75) 2.23 (0.89) 2.24 (0.95) 2.18 (0.92)
HTS 2.28 (0.87) 2.36 (0.91) 2.41 (0.88) 2.37 (0.90)
FVC 0.62
IS 3.23 (0.95) 3.26 (1.07) 3.22 (1.1) 3.14 (1.12)
HTS 3.27 (1.00) 3.31 (1.11) 3.32 (1.07) 3.25 (1.06)
FEF25e75% 0.41
IS 1.39 (0.85) 1.61 (1.07) 1.71 (1.20) 1.57 (0.98)
HTS 1.62 (1.02) 1.73 (0.98) 1.87 (1.14) 1.86 (1.08)
Data are mean (standard deviation). FEV1: forced expiratory volume in 1 s, FVC: forced vital capacity, FEF25e75%: forced expiratory flow
at 25e75% of the forced vital capacity, IS: isotonic saline, HTS: hypertonic saline. p value for group  time interaction.
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baseline, are likely to be clinically relevant as they go
against the expected trend of gradual decline in this
cohort of patients.1 However, the decrease in lung func-
tion and QOL between the six and 12 month visits is likely
to reflect the significant decrease in adherence to therapy
in both groups over this period and suggests that, for this
treatment to be effective, it needs to be undertaken on
a regular basis.
The improvements seen in both groups may have been
due to the inhalation of the saline solution or alternatively
could be due to pre-medication with Salbutamol. It is
unlikely however that this would be the case. A short term
four arm study showed an increased sputum yield in both
the IS and HTS groups compared to Terbutaline alone,
suggesting that Salbutamol was unlikely to have contrib-
uted markedly to the improvement seen in both groups.17
The analysis of exacerbations is complicated by the
lack of a standardised definition of an exacerbation in this
population of patients25 and the relatively small sample
size may have masked any differences between groups in
exacerbation rates. In non-CF bronchiectasis the
improvement in QOL is one of the most important outcome
measures.1,28 An association between more frequent
exacerbations and lower QOL has previously been
demonstrated in non-CF bronchiectasis5,19 and given the
significant improvements in QOL demonstrated here, it is
possible that there was an associated reduction in exac-
erbation rate in both groups compared to the previous
year. A 12 month run-in period recording exacerbations
would have been ideal to ascertain if this was the case and
should be investigated in larger studies. The small number
of hospital admissions may possibly be attributed to
increased clinical management as a result of participating
in the trial.
A possible limitation of the trial was that the taste of the
saline solutions was not masked by the addition of quinine
(previously used as a blinding agent).16,29 As participants
were naı¨ve to nebulised saline, were not informed of the
salt concentration of the challenge test and packaging of
the two solutions was identical, we are confident that
participants remained blinded. In a recent study involving
the inhalation of IS (where a salty taste is not expected),
17% of patients reported a salty taste.30 Importantly, at
trial completion, only 50% of the participants correctlyidentified their treatment allocation so the taste of the
solution was unlikely to have biased the study.
Isotonic saline is a commonly used placebo for studies of
inhaled medications16,30 however, the improvements iden-
tified over 12 months suggest that IS itself may have benefi-
cial effects, possibly through hydration of the airway. This is
consistent with previous studies that have shown improve-
ment in QOL30 and lung function with IS.16,17 The benefits
seen in these studies are consistent with a recent trial which
showed a significant improvement in QOL and a decrease in
exacerbation days following the long term humidification of
the airways in patients with non-CF bronchiectasis.31
In conclusion, this study demonstrates that the long
term inhalation of a saline solution in patients with non-CF
bronchiectasis is a safe and possibly clinically beneficial
treatment which results in improvements in QOL, lung
function and sputum colonisation. The effect on exacer-
bation rate needs to be examined in a larger study. Choice
of an inhaled saline therapy may be guided by individual
patient tolerance and preference.
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